ONTARIO, Calif., Aug. 2, 2004 (PRIMEZONE) -- LifePoint Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced that the Tulsa Police Department, Tulsa, Oklahoma became the first Police Department to adopt the IMPACT(r) Test System to test juveniles found living at locations under investigation for distribution or manufacture of illegal drugs, such as methamphetamine laboratories.
"The LifePoint(r) IMPACT(r) Test System has proven to be a valuable tool in ensuring the welfare of juveniles who may have been exposed to illegal drugs, directly or indirectly, as a result of activities in and around their homes," stated the agency narcotics task force spokesman. "The ability to quickly, easily, and accurately determine a child's exposure to drug use in his or her home using the saliva-based IMPACT(r) Test System enables our department to act much faster and more efficiently than compared to waiting for the collection and testing for a urine sample. IMPACT(r) allows us to collect the sample, process it and obtain the complete drug test results faster than we can even collect the urine sample. Additionally, we've found that the non-invasive saliva-based test procedure doesn't frighten or intimidate the kids."
"We are pleased to announce that the LifePoint IMPACT(r) Test System is finding new applications within the law enforcement community," stated Linda H. Masterson, President and CEO of LifePoint Inc. "Our initial focus for law enforcement and criminal justice has been for use in the drug court system and for establishing a base of referral accounts for DUI testing. We have been pleasantly surprised by some of the other advantages our product provides to law enforcement work - such as in drug raids and narcotics operations. The more uses for our product in a single location, the more compelling the selling story."
About LifePoint, Inc
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT(r) Test System - a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets - law enforcement, industrial workplace and medical emergency room - are estimated at over $1.6 billion in total sales opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the potential need for additional financing, FDA 510(k) clearance in medical markets, dependence on third parties for certain marketing efforts, and market acceptance. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.